Business · India Bureau
Moderna Stock Tumbles on Citi Downgrade; Rare Bearish Call Sparks Selloff
Shares of vaccine maker Moderna fell sharply following a bearish analyst rating from Citigroup, marking only the third sell recommendation among roughly two dozen analysts tracking the stock. The downgrade triggered significant selling pressure in the market.
LSN India ·
Moderna Inc.'s stock declined 8 per cent following a bearish call from Citigroup analysts, signalling growing concerns about the pharmaceutical company's near-term prospects. The downgrade proved consequential given the relatively rare occurrence of negative ratings on the company's shares, which have historically commanded broad analyst support.
The Citigroup assessment stands out as particularly notable because Moderna had previously attracted only two Sell ratings among approximately two dozen Wall Street analysts covering the stock. The bearish stance suggests a shift in institutional sentiment toward the company, which has faced headwinds amid declining demand for COVID-19 vaccines and ongoing competition in the immunology space.
The market reaction underscores investor sensitivity to analyst recommendations, particularly when they diverge significantly from consensus views. The sell-off reflects broader concerns about Moderna's revenue trajectory and pipeline execution as the company navigates the transition away from pandemic-driven vaccine demand toward its diversified product portfolio.
Analysts remain divided on the stock's outlook, though the preponderance of bullish ratings had previously supported valuations. The Citigroup downgrade may prompt a broader reassessment of the company's growth prospects among institutional investors in coming sessions.